Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 36Stomach Neoplasms 9Colonic Neoplasms 6Rectal Neoplasms 3Sarcoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1NSCLC 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumors 1Advanced Pancreatic Carcinoma 1Advanced Gastric Cancer 1

Interventions

Fluorouracil 8Bevacizumab 8Oxaliplatin 7Leucovorin 7Irinotecan 7Capecitabine 7Cetuximab 6Panitumumab 4sintilimab 2regorafenib 2aflibercept 2tremelimumab 1spartalizumab 1pembrolizumab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1atezolizumab 1anisodamine 1SHR-1701 1Radiotherapy 1Pemetrexed 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Lycopene 1Loperamide 1Ipilimumab 1HMPL-013 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Cancer Metastatic × HMPL-013 × Clear all
NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡